カテゴリ： Grand View Research, 世界, 医療/バイオ

特発性血小板減少性紫斑病（ITP）治療薬の世界市場2023-2030：市場規模、シェア、動向分析

■ 英語タイトル：Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Corticosteroids, IVIG, Anti-D Immunoglobulins, TPO-RA, Others), By Region, And Segment Forecasts, 2023 - 2030

調査会社Grand View Research社が発行したリサーチレポート（データ管理コード：GRV23NVB124）■ 発行会社/調査会社：Grand View Research
■ 商品コード：GRV23NVB124
■ 発行日：2023年10月19日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：60
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後3営業日）
■ 販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[特発性血小板減少性紫斑病（ITP）治療薬の世界市場2023-2030：市場規模、シェア、動向分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

特発性血小板減少性紫斑病（ITP）治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、特発性血小板減少性紫斑病（ITP）治療薬の世界市場は、2023年から2030年にかけて年平均成長率5.0%で拡大し、2030年までに9億1490万米ドルに達する見込みです。 IVIGやTPO-RAクラスの新薬導入につながる研究開発の増加が、予測期間中の成長を促進する見込みです。さらに、新製品の開発を奨励する目的で、米国では希少疾病用医薬品法（Orphan Drug Act）などの政府規制があり、これが成長を促進すると予測されています。

併用療法は他の治療法に比べて高い効率を示すため、需要の高まりがこの業界の特徴です。さらに、費用効率が高く、個々の治療クラスに関連する副作用の抑制にも役立ちます。主な併用療法には、デキサメタゾンとリツキシマブ、デキサメタゾンとTPO-RA、IVIG、コルチコステロイドなどがあります。脾臓摘出術は、抗血小板抗体の量を減少させることを目的とした脾臓を摘出する手術であり、需要に拍車がかかると予想されます。副腎皮質ステロイドは特発性血小板減少性紫斑病の治療に定期的に使用されています。副腎皮質ステロイドはITP患者の治療の第一選択薬と考えられているため、副腎皮質ステロイドの使用率は非常に高くなっています。

特発性血小板減少性紫斑病（ITP）治療薬市場レポートハイライト

- TPO-RAは、エルトロンボパグとロミプロスチムを投与された患者の奏効率が高いことから、2023年から2030年にかけてCAGR 6.6%以上で成長し、大幅な成長が見込まれます。さらに、2015年にアバトロンボパグが商業化されたことにより、TPO-RAの需要が増加する見込みです。加えて、TPO-RAは脾臓摘出患者の再発に対応できることから、今後6年間の需要拡大が見込まれます。

- 北米が市場を支配し、2022年には39.9%の最大売上シェアを占めました。

- アジア太平洋地域は予測期間中、最も速いCAGR 6.2%で成長する見込みです。

- アジア太平洋地域は、オーストラリアと日本における政府の積極的な取り組みや高度な医療インフラの存在により、今後6年間で大幅な成長が見込まれています。加えて、中国やインドなどの新興市場には未開拓のビジネスチャンスが豊富に存在するため、成長が促進される見込みです。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 特発性血小板減少性紫斑病（ITP）治療薬の市場変数・傾向・範囲
第4章. 特発性血小板減少性紫斑病（ITP）治療薬の世界市場：疾患種類別予測・傾向分析
第5章. 特発性血小板減少性紫斑病（ITP）治療薬の世界市場：製品別予測・傾向分析
第6章. 特発性血小板減少性紫斑病（ITP）治療薬の世界市場：地域別予測・傾向分析
第7章. 競争状況

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Disease Type
1.1.2. Product
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease type outlook
2.2.2. Product outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Disease Type Key Takeaways
4.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Acute ITP
4.3.1. Acute ITP market estimates and forecasts, 2018 to 2030, (USD Million)
4.4. Chronic
4.4.1. Chronic market estimates and forecasts, 2018 to 2030, (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 5. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Product Estimates & Trend Analysis
5.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product Key Takeaways
5.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Corticosteroids
5.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030, (USD Million)
5.4. IVIG
5.4.1. IVIG market estimates and forecasts, 2018 to 2030, (USD Million)
5.5. Anti-D Immunoglobulins
5.5.1. Anti-D Immunoglobulins market estimates and forecasts, 2018 to 2030, (USD Million)
5.6. TPO-RA
5.6.1. TPO-RA market estimates and forecasts, 2018 to 2030, (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 6. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. U.K.
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Amgen Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Disease Type benchmarking
7.2.1.4. Strategic initiatives
7.2.2. F. Hoffmann-La Roche Ltd
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Disease Type benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Grifols, S.A.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Disease Type benchmarking
7.2.3.4. Strategic initiatives
7.2.4. GSK plc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Disease Type benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Shangxian Minimal Invassive Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Disease Type benchmarking
7.2.5.4. Strategic initiatives
7.2.6. INTROMEDIC
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Disease Type benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Medtronic
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Disease Type benchmarking
7.2.7.4. Strategic initiatives
7.2.8. FUJIFILM Holdings Corporation
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Disease Type benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Olympus Corporation
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Disease Type benchmarking
7.2.9.4. Strategic initiatives
7.2.10. JINSHAN Science & Technology (Group) Co., Ltd.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Disease Type benchmarking
7.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 3 North America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 4 North America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
Table 5 U.S. idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 6 U.S. idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 7 Canada idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 8 Canada idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 9 Europe idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 10 Europe idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 11 Europe idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
Table 12 Germany idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 13 Germany idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 14 UK idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 15 UK idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 16 France idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 17 France idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 18 Italy idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 19 Italy idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 20 Spain idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 21 Spain idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 22 Denmark idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 23 Denmark idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 24 Sweden idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 25 Sweden idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 26 Norway idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 27 Norway idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 28 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
Table 31 Japan idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 32 Japan idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 33 China idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 34 China idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 35 India idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 36 India idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 37 Thailand idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 38 Thailand idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 39 South Korea idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 40 South Korea idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 41 Latin America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 42 Latin America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 43 Latin America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018 - 2030 (USD Million)
Table 44 Brazil idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 45 Brazil idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 46 Mexico idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 47 Mexico idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 48 Argentina idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 49 Argentina idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 50 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 51 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018 - 2030
Table 53 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 54 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 55 South Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 56 South Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 57 UAE idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 58 UAE idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)
Table 59 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 60 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by product, 2018 - 2030 (USD Million)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ヒト免疫不全ウイルス（HIV）治療薬の世界市場2023-2030：市場規模、シェア、動向分析
  • 膣炎治療薬の世界市場2023-2030：市場規模、シェア、動向分析
  • 世界の医療用チューブ市場2023-2030：市場規模、シェア、動向分析
  • 精密医療の世界市場2023-2030：市場規模、シェア、動向分析
  • 世界の静脈注射用鉄剤市場2023-2030：市場規模、シェア、動向分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GRV23NVB124 )"特発性血小板減少性紫斑病（ITP）治療薬の世界市場2023-2030：市場規模、シェア、動向分析" (英文：Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Corticosteroids, IVIG, Anti-D Immunoglobulins, TPO-RA, Others), By Region, And Segment Forecasts, 2023 - 2030)はGrand View Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。